Retail sales of prescription drugs will exceed $100 billion this year, according to the National Association of Chain Drug Stores. Ronald L. Ziegler, president and CEO of the association, made the history-making announcement at the 41st NACDS Pharmacy Conference & Managed Care Forum in San Diego in August.
Retail sales of prescription drugs will exceed $100 billion this year, according to the National Association of Chain Drug Stores. Ronald L. Ziegler, president and CEO of the association, made the history-making announcement at the 41st NACDS Pharmacy Conference & Managed Care Forum in San Diego in August.
By the end of 1998, Ziegler said, sales of prescription products will have reached $102.5 billion, an increase of more than 15% over last year. In 1997, sales reached $89 billion. That accounts for 2.8 billion dispensed prescriptions, which is an increase of 6% from the 2.6 billion prescriptions dispensed in 1997.
Heavy managed care penetration has certainly contributed to the rise in prescription volume, as have an aging population, an increase in advertising and faster drug approval times. In recent years, managed care organizations have become more amenable to covering plan members' prescription drug costs because they believe it is ultimately less expensive therapy than more invasive procedures.
Chain community pharmacies, such as traditional chain drug stores, mass merchant chain pharmacies and supermarket chain pharmacies, will account for 61% of $102.5 billion in sales, dispensing more than 60% of the total amount of prescriptions.
NACDS predicted that the growth in prescriptions dispensed at community pharmacies will continue, and could reach a staggering 4 billion in the year 2005. For comparison, the number of retail prescriptions dispensed in 1992 was just over 2 billion. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.